Literature DB >> 3989697

Comparative bioavailability and pharmacokinetics of three formulations of albuterol.

M L Powell, M Weisberger, R Gural, M Chung, J E Patrick, E Radwanski, S S Symchowicz.   

Abstract

Albuterol sulfate, alpha'[[1,1-dimethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol sulfate, is a relatively selective beta-2-adrenergic bronchodilator used for the relief of bronchospasm. The bioavailability of two 4-mg tablet formulations, differing in their inactive excipients, and a syrup formulation, was evaluated. The three dosage forms were orally administered to 12 normal male volunteers in a randomized three-way crossover study. Plasma samples were collected at frequent time points through 12 h and analyzed for albuterol content by a specific GC-MS method. The drug was rapidly absorbed from all three formulations. Maximum drug concentrations were comparable for the three formulations and were obtained between 1.8-2.0 h. The areas under the plasma concentration-time curves were 68-78 h X ng/mL. The drug elimination phase half-live (t1/2 beta) ranged from 4.8 to 5.5 h. Analysis of the data showed that the bioavailability of albuterol from a tablet formulation is equivalent to that from a solution.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3989697     DOI: 10.1002/jps.2600740225

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Additive Effects of Alcohols, Their Acidic By-Products, and Temperature on the Yeast Pachysolen tannophilus.

Authors:  M de F Barbosa; H Lee; D L Collins-Thompson
Journal:  Appl Environ Microbiol       Date:  1990-02       Impact factor: 4.792

2.  Continuous-Culture Responses of Candida shehatae to Shifts in Temperature and Aeration: Implications for Ethanol Inhibition.

Authors:  M A Alexander; T W Chapman; T W Jeffries
Journal:  Appl Environ Microbiol       Date:  1989-09       Impact factor: 4.792

3.  Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.

Authors:  D J Morgan; J D Paull; B H Richmond; E Wilson-Evered; S P Ziccone
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 4.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

5.  Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Katia Collomp; Juliette Carra; Fabio Borrani; Olivier Coste; Christian Préfaut; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-01-10       Impact factor: 3.078

6.  Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects.

Authors:  E Rey; L Luquel; M O Richard; B Mory; G Offenstadt; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers.

Authors:  D A Goldstein; Y K Tan; S J Soldin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.